Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

被引：0
|
作者：
Jinlin Song
Qiufei Ma
Wei Gao
Ze Cong
Jipan Xie
Zachary Zimmerman
Laura Belton
Janet Franklin
Stephen Palmer
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Amgen Inc.,undefined
[4] Analysis Group,undefined
[5] Inc.,undefined
[6] LB Biostatistics,undefined
[7] Centre for Health Economics,undefined
[8] University of York,undefined
来源：
Advances in Therapy | 2019年 / 36卷
关键词：
Blinatumomab; Complete remission; Inotuzumab ozogamicin; Matching-adjusted indirect comparison; Overall survival; Relapsed or refractory acute lymphoblastic leukemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：950 / 961
页数：11
相关论文
共 50 条
  • [21] Inotuzumab Ozogamicin, a Nonchemotherapy Option for Relapsed Acute Lymphoblastic Leukemia
    Kantarjian, Hagop M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 268 - 270
  • [22] Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia
    Ohana, Zahava
    Serraes, Samantha
    Elder, Christopher
    Katusa, Nikolina
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (05) : 1269 - 1275
  • [23] Quality-adjusted life years (QALY) for inotuzumab ozogamicin vs standard of care for relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Van Oostrum, Ilse
    Su, Yun
    Heeg, Bart
    Wilke, Thomas
    Smith, Alexander
    Loberiza, Fausto Rodriguez
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
    Fracchiolla, Nicola Stefano
    Sciume, Mariarita
    Papayannidis, Cristina
    Vitale, Antonella
    Chiaretti, Sabina
    Annunziata, Mario
    Giglio, Fabio
    Salutari, Prassede
    Forghieri, Fabio
    Lazzarotto, Davide
    Lunghi, Monia
    Imovilli, Annalisa
    Scappini, Barbara
    Bonifacio, Massimiliano
    Dargenio, Michelina
    Gurrieri, Carmela
    Todisco, Elisabetta
    Defina, Marzia
    Del Principe, Maria Ilaria
    Zappasodi, Patrizia
    Cerrano, Marco
    Santoro, Lidia
    Tagliaferri, Elena
    Barozzi, Enrico
    De Roberto, Pasquale
    Canzi, Marta
    Buzzatti, Elisa
    Sartor, Chiara
    Passamonti, Francesco
    Foa, Robin
    Curti, Antonio
    Wirth, Thomas
    CANCERS, 2023, 15 (18)
  • [25] QUALITY-ADJUSTED LIFE YEARS (QALY) FOR INOTUZUMAB OZOGAMICIN VS STANDARD OF CARE FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL)
    van Oostrum, I.
    Su, Y.
    Heeg, B.
    Wilke, T.
    Smith, A.
    Loberiza, F. R.
    HAEMATOLOGICA, 2017, 102 : 347 - 347
  • [26] A Case in Which Relapsed Acute Lymphoblastic Leukemia was Treated With Blinatumomab and Inotuzumab Ozogamicin in A Down's Syndrome Patient
    Ono, Takahiro
    Akiyama, Kosuke
    Takamido, Shotaro
    Yamaoka, Daishiro
    Takagi, Toshiyuki
    Ujiie, Gakuto
    Kanazawa, Takeru
    Kaneko, Ryota
    Okamoto, Naoko
    Koganesawa, Masaya
    Fujita, Sachio
    Ogawa, Rei
    Suzuki, Manabu
    Matsuno, Ryosuke
    Toyama, Daisuke
    Fujimoto, Yoko
    Ikeda, Hirokazu
    Yamamoto, Shohei
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S28 - S29
  • [27] Inotuzumab Ozogamicin (Besponsa®) for Patients with relapsed or refractory acute lymphoblastic Leukemia (r/r ALL)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 66 - 66
  • [28] Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia
    Naohito Fujishima
    Toshiki Uchida
    Yasushi Onishi
    Chul Won Jung
    Yeow Tee Goh
    Kiyoshi Ando
    Ming Chung Wang
    Chiho Ono
    Miyako Matsumizu
    M. Luisa Paccagnella
    Barbara Sleight
    Erik Vandendries
    Yosuke Fujii
    Masayuki Hino
    International Journal of Hematology, 2019, 110 : 709 - 722
  • [29] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali
    Rodriguez, Vilmarie
    O'Brien, Maureen Megan
    McNeer, Jennifer Lynn
    Loh, Mignon L.
    Rheingold, Susan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia
    Fujishima, Naohito
    Uchida, Toshiki
    Onishi, Yasushi
    Jung, Chul Won
    Goh, Yeow Tee
    Ando, Kiyoshi
    Wang, Ming Chung
    Ono, Chiho
    Matsumizu, Miyako
    Paccagnella, M. Luisa
    Sleight, Barbara
    Vandendries, Erik
    Fujii, Yosuke
    Hino, Masayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) : 709 - 722
12345